Table 2.
Target‐site | Line | N * | Developmental time ± SE | ISS ± SE | FR ± SE | FFD ± SE | TF ± SE | |
---|---|---|---|---|---|---|---|---|
Male | Female | |||||||
CHS1 (wt) | CHS1_C | 906 | 9.32 ± 0.12a | 9.68 ± 0.08a | 0.59 ± 0.044a | 0.65 ± 0.045a | 6.28 ± 0.32a | 91.03 ± 8.86a |
CHS1 (I1017F) | CHS1_R1 | 710 | 9.90 ± 0.06b | 10.38 ± 0.08b | 0.63 ± 0.052a | 0.67 ± 0.052a | 5.52 ± 0.30a | 105.41 ± 10.26a |
CHS1_R2 | 752 | 9.96 ± 0.15b | 10.39 ± 0.17b | 0.64 ± 0.048b | 0.72 ± 0.051b | 5.87 ± 0.30a | 128.06 ± 10.42b | |
CHS1_R3 | 1,132 | 9.93 ± 0.09b | 10.36 ± 0.09b | 0.58 ± 0.042a | 0.65 ± 0.044a | 6.57 ± 0.58a | 86.06 ± 7.27a | |
VGSC (wt) | VGSC_C | 969 | 10.95 ± 0.23a | 11.45 ± 0.20a | 0.66 ± 0.031a | 0.67 ± 0.031a | 8.06 ± 0.214a | 101.58 ± 6.33a |
VGSC (L1024V) | VGSC_R2 | 1,157 | 10.89 ± 0.16a | 11.20 ± 0.18a | 0.72 ± 0.02b | 0.75 ± 0.026b | 7.66 ± 0.204a | 94.88 ± 5.69a |
VGSC_R3 | 1,461 | 11.0 ± 0.06a | 11.63 ± 0.07a | 0.66 ± 0.025a | 0.69 ± 0.025a | 8.12 ± 0.296a | 93.87 ± 6.76a | |
Cytb (wt) | Wasatch | 1,408 | 9.67 ± 0.38a | 10.17 ± 0.38a | 0.60 ± 0.037a | 0.66 ± 0.037a | 5.53 ± 0.28a | 92.64 ± 7.85a |
Cytb (P262T) | cytb_R1 | 1,498 | 9.92 ± 0.46a | 10.35 ± 0.50a | 0.69 ± 0.035b | 0.75 ± 0.034b | 6.42 ± 0.28a | 113.09 ± 8.04a |
cytb_R2 | 1,078 | 10.17 ± 0.38a | 10.73 ± 0.37b | 0.63 ± 0.042b | 0.76 ± 0.040b | 4.42 ± 0.27b | 71.46 ± 8.13a | |
cytb_R3 | 1,132 | 9.98 ± 0.18a | 10.79 ± 0.23b | 0.61 ± 0.042a | 0.65 ± 0.042a | 5.04 ± 0.19a | 94.66 ± 6.45a | |
GluCl1+3 (wt) | GluCl1+3_C | 1,124 | 9.78 ± 0.09a | 10.16 ± 0.06a | 0.77 ± 0.025a | 0.77 ± 0.025a | 8.32 ± 0.30a | 123.09 ± 9.64a |
GluCl1+3 (G314D+G326E) | GluCl1+3_R1 | 1,890 | 10.03 ± 0.06a | 10.28 ± 0.06a | 0.35 ± 0.022b | 0.43 ± 0.025b | 7.22 ± 0.34b | 93.61 ± 9.12a |
GluCl1+3_R2 | 1,244 | 10.29 ± 0.12b | 10.48 ± 0.10b | 0.72 ± 0.026b | 0.76 ± 0.025a | 6.66 ± 0.36b | 105.81 ± 10.32a | |
GluCl1+3_R3 | 1,194 | 10.23 ± 0.06b | 10.42 ± 0.06b | 0.66 ± 0.027b | 0.67 ± 0.028b | 7.33 ± 0.344b | 120.10 ± 10.47a |
Development time (d): time required for ≥50% males and females to emerge, TF: eggs/female, FFD: eggs/female/day, ISS: % females reaching adulthood, FR: % females in the progeny. Means followed by the letter “a” within a column are not significantly different from the control line (adjusted p‐value <0.05). *Initial number of eggs. Comparisons where all mutation‐carrying lines significantly differed from the susceptible control are indicated in bold.